Integration of all these molecular vulnerabilities will hopefully help expanding our knowledge on the role of the microenvironment in DLBCL pathobiology and contribute to the rationale for novel PD-1/PD-L1-related combination immunotherapies for this disease. This evidence concerns the gene CD274 and diffuse large B-cell lymphoma.